drugset / Trial / NCT04956666
A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Phase 2
Completed
75 enrolled
Servier
ADIR, a Servier Group company · collabLes Laboratoires Servier (L.L.S), Russia · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide treatment with lyophilized S95014 in pediatric patients with ALL who completed the CL2-95014-002 study during the induction phase and who are clinically benefitting from S95014 without major toxicity.
Timeline
- Start
- 2021-06-15
- Primary completion
- 2023-01-23
- Completion
- 2023-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegaspargase | Protein / enzyme biologic | 1000 unknown | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2000 unknown | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intravenous |